Columbia University is one of the leading programs in the United States conducting a groundbreaking Phase 2 clinical trial of an investigational gene therapy for dry age-related macular degeneration.

NewYork-Presbyterian obstetricians and gynecologists continue to investigate COVID-19 and its potential impact on pregnancy outcomes, including studies on serial testing for SARS-CoV-2 and vaccinations.

The latest advance in radiation therapy—using AI to adjust treatments on the fly—is now available for select cancer patients at NewYork-Presbyterian/Columbia University Irving Medical Center.

A simple surgical technique during cardiac surgery was associated with a 56 percent reduction in the incidence of an irregular heart rhythm known as atrial fibrillation that can lead to stroke, with no added risks or side effects.

NewYork-Presbyterian, one of the nation’s most comprehensive, integrated academic healthcare systems, today launched “Stay Amazing,” its first new brand platform and campaign in more than a decade.

Columbia University Irving Medical Center with NewYork-Presbyterian has been named a Center of Excellence by the National Organization for Rare Disorders (NORD) and joins a national network dedicated to improving treatment and care for people with rare diseases.

It is estimated that nearly 3.4 million Americans are currently diagnosed with epilepsy; 470,000 are children ages 14 and younger.

Neurologists and critical care medicine specialists at NewYork-Presbyterian Hospital offer highly specialized expertise in disorders of consciousness to promote the best outcomes for patients.